US80810D1037 - Common Stock
SCHRODINGER INC
NASDAQ:SDGR (5/3/2024, 7:17:38 PM)
After market: 23.4716 -0.21 (-0.88%)23.68
+0.49 (+2.11%)
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 787 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The firm also leverages its software platform to advance collaborative programs and its own pipeline of therapeutics to address unmet medical needs. The firm operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software to transform molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), SOS1/KRAS inhibitor program, and LRRK2 Inhibitor Program.
SCHRODINGER INC
1540 Broadway, 24th Floor
New York City NEW YORK 10036
P: 15032991150
CEO: Ramy Farid
Employees: 787
Website: https://www.schrodinger.com
SDGR stock results show that Schrodinger missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Schrodinger (NASDAQ:SDGR) just reported results for the first quarter of 2024.S...
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Here you can normally see the latest stock twits on SDGR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: